Abstract
Purpose
Neoadjuvant therapy followed by surgical resection is one of the preferred treatment option for locally advanced non-small cell lung cancer (NSCLC). For patients with mesenchymal-epithelial transition (MET) factor exon 14 skipping (METex14) mutations, the use of MET-tyrosine kinase inhibitors (TKIs) showed high efficiency and reduced toxicity compared with first-line standard chemotherapy. However, it is unknown whether preoperative induction targeted therapy of MET-TKIs is feasible and safe.
Methods
Here, we reported 3 cases of locally advanced unresectable NSCLC with METex14 mutations receiving induction therapy of MET-TKI savolitinib as first-line therapy or second-line therapy when they experienced disease progression after preoperative chemotherapy.
Results
All these 3 patients achieved significant tumor size shrinkage and their unresectable tumors became resectable after the treatment of savolitinib. No serious adverse events were observed during the treatment. They recovered well postoperatively, and no significant events were identified.
Conclusions
Preoperative induction treatment with MET-TKI savolitinib showed its safety and effectiveness and may be an alternative option for neoadjuvant therapy for NSCLC patients with METex14 mutations.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Choueiri TK, Heng DYC, Lee JL, Cancel M, Verheijen RB, Mellemgaard A et al (2020) Efficacy of Savolitinib vs Sunitinib in patients with MET-driven papillary renal cell carcinoma: the SAVOIR phase 3 randomized clinical trial. JAMA Oncol 6(8):1247–1255
Deng HY, Li D, Ren Y, Wang K, Tang X (2021) Targeted therapy followed by salvage surgery and adjuvant therapy: a promising therapy for lung cancer with malignant pleural effusion from a case report. Front Surg 8:659983
Dhillon S (2020) Capmatinib: first approval. Drugs 80(11):1125–1131
Group NM-aC (2014) Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet 383(9928):1561–1571
Guo R, Luo J, Chang J, Rekhtman N, Arcila M, Drilon A (2020) MET-dependent solid tumours—molecular diagnosis and targeted therapy. Nat Rev Clin Oncol 17(9):569–587
Jia H, Dai G, Weng J, Zhang Z, Wang Q, Zhou F et al (2014) Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (volitinib) as a highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitor in clinical development for treatment of cancer. J Med Chem 57(18):7577–7589
Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II et al (2014) using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311(19):1998–2006
Lee J, Kim ST, Kim K, Lee H, Kozarewa I, Mortimer PGS et al (2019) Tumor genomic profiling guides patients with metastatic gastric cancer to targeted treatment: the VIKTORY umbrella trial. Cancer Discov 9(10):1388–1405
Lu S, Fang J, Li X, Cao L, Zhou J, Guo Q et al (2021) Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study. Lancet Respir Med 9(10):1154–1164
Markham A (2020) Tepotinib: first approval. Drugs 80(8):829–833
Markham A (2021) Savolitinib: first approval. Drugs 81(14):1665–1670
National comprehensive cancer network. Non-small cell lung cancer (Version: 3.2022) [Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
Rotow JK, Woodard GA, Urisman A, McCoach CE, Bivona TG, Elicker BM et al (2019) Pathologic complete response to neoadjuvant crizotinib in a lung adenocarcinoma patient with a MET Exon 14 skipping mutation. Clin Lung Cancer 20(2):e137–e141
Sequist LV, Han JY, Ahn MJ, Cho BC, Yu H, Kim SW et al (2020) Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol 21(3):373–386
Vuong HG, Ho ATN, Altibi AMA, Nakazawa T, Katoh R, Kondo T (2018) Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer—a systematic review and meta-analysis. Lung Cancer 123:76–82
Wang Y, Liu T, Chen G, Gong J, Bai Y, Zhang T et al (2022) Phase Ia/Ib study of the selective MET inhibitor, savolitinib, in patients with advanced solid tumors: safety, efficacy, and biomarkers. Oncologist 27(5):342-e83
Yang JJ, Fang J, Shu YQ, Chang JH, Chen GY, He JX et al (2021) A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer. Invest New Drugs 39(2):477–87
Zhang C, Li SL, Nie Q, Dong S, Shao Y, Yang XN et al (2019) Neoadjuvant crizotinib in resectable locally advanced non-small cell lung cancer with ALK rearrangement. J Thorac Oncol 14(4):726–731
Zhang Y, Fu F, Hu H, Wang S, Li Y, Hu H et al (2021) Gefitinib as neoadjuvant therapy for resectable stage II-IIIA non-small cell lung cancer: a phase II study. J Thorac Cardiovasc Surg 161(2):434–42.e2
Zhong W-Z, Chen K-N, Chen C, Gu C-D, Wang J, Yang X-N et al (2019) Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non–small-cell lung cancer (EMERGING-CTONG 1103): a randomized phase II study. J Clin Oncol 37(25):2235–2245
Acknowledgements
We thank sincerely for the efforts from the staffs of Astrazeneca in data collection and anlysis.
Funding
This work was supported by the Department of Science and Technology of Sichuan Province (2022JDKP0009).
Author information
Authors and Affiliations
Contributions
H-YD collected and analyzed data and drafted the manuscript. H-YD and QZ designed the study. X-MQ, D-XZ, and X-JT, and QZ revised the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Conflict of interest
None declared.
Ethical approval
This work was approved by the Ethics Committee of West China Hospital of Sichuan University(No.2021–332).
Informed consent
Informed consent was obtained from all these patients.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Deng, HY., Qiu, XM., Zhu, DX. et al. The safety and feasibility of preoperative induction therapy of Savolitinib in non-small cell lung cancer patients with MET exon 14 skipping mutation. J Cancer Res Clin Oncol 149, 4623–4628 (2023). https://doi.org/10.1007/s00432-022-04370-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-022-04370-x